REG - Hikma Pharmaceutical - Total Voting Rights <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

06/09/2014 16:30

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20140714:nRSN2694Ma


RNS Number : 2694M
Hikma Pharmaceuticals Plc
14 July 2014 
 
Hikma Pharmaceuticals PLC 
 
Voting Rights and Capital 
 
LONDON, 14 July 2014, Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)
notifies the market that its capital consists of 198,525,524 ordinary shares
with voting rights. There are nil shares held in treasury. 
 
The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under
the FCA's Disclosure and Transparency Rules. 
 
- ENDS - 
 
Enquiries 
 
 Hikma Pharmaceuticals PLC                        
 Peter SpeirsCompany Secretary  +44 20 7399 2760  
                                                    
 
 
About Hikma 
 
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed products.  Hikma's operations are
conducted through three businesses: "Branded", "Injectables" and "Generics"
based primarily in the Middle East and North Africa ("MENA") region, where it
is a market leader, the United States and Europe.  In 2013, Hikma achieved
revenues of $1,365 million and profit attributable to shareholders of $212
million. 
 
This information is provided by RNS
The company news service from the London Stock Exchange